Tectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Piper Sandler

Investment analysts at Piper Sandler began coverage on shares of Tectonic Therapeutic (NASDAQ:TECX) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $76.00 price target on the stock. Piper Sandler’s target price suggests a potential upside of 360.89% from the company’s previous close.

Separately, TD Cowen initiated coverage on Tectonic Therapeutic in a research report on Monday. They set a “buy” rating on the stock.

Tectonic Therapeutic Price Performance

TECX opened at $16.49 on Wednesday. The firm has a market cap of $740.24 million, a PE ratio of 23.90 and a beta of 1.23. Tectonic Therapeutic has a fifty-two week low of $10.56 and a fifty-two week high of $19.80.

Tectonic Therapeutic (NASDAQ:TECX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.